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Neurodegeneration with brain iron
accumulation (NBIA)
Magnetic resonance imaging (MRI)
Neuroimaging
SyndromesIron participates in a wide array of cellular functions and is essential for normal neural development and
physiology. However, if inappropriately managed, the transition metal is capable of generating neurotoxic
reactive oxygen species. A number of hereditary conditions perturb body iron homeostasis and some,
collectively referred to as neurodegeneration with brain iron accumulation (NBIA), promote pathological
deposition of the metal predominantly or exclusively within the central nervous system (CNS). In this article,
we discuss seven NBIA disorders with emphasis on the clinical syndromes and neuroimaging. The latter
primarily entails magnetic resonance scanning using iron-sensitive sequences. The conditions considered are
Friedreich ataxia (FA), pantothenate kinase 2-associated neurodegeneration (PKAN), PLA2G6-associated
neurodegeneration (PLAN), FA2H-associated neurodegeneration (FAHN), Kufor-Rakeb disease (KRD),
aceruloplasminemia, and neuroferritinopathy. An approach to differential diagnosis and the status of iron
chelation therapy for several of these entities are presented. This article is part of a Special Issue entitled:
Imaging Brain Aging and Neurodegenerative disease.: Imaging Brain Aging and
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Iron is critical for normal neuroembryogenesis and physiology and
participates in a wide spectrum of cellular functions including
cytokinesis, myelination, electron transport, antioxidant enzyme activ-
ity and biogenic amine metabolism [1]. While allowing for this
bioversatility, the electronic properties of this transition metal enable
iron to take part in chemical reactions that may be injurious to neural
and other cellular substrates. Iron plays a pivotal role in cellular redox
chemistry by reducing H2O2 to the highly-cytotoxic hydroxyl (OH•)
radical (Fenton catalysis) or by behaving as pseudoperoxidase activity
that bio-activates benign compounds (e.g. catechols) into toxic free
radical intermediates. Various biochemical and physiological charac-
teristics of themammalian CNS render it particularly vulnerable to iron-
and redox-related damages. Some of the more important of these are
(i) the robust ﬂux of molecular oxygen in normally-respiring neural
tissues, (ii) excessive generation of reactive oxygen species (ROS) by
effete mitochondria in aging post-mitotic neurons, (iii) susceptibility of
the CNS to lipid peroxidation accruing from its high cholesterol and
unsaturated fat (C20:5, C22:6) content, (iv) the abundance of oxidizable(e.g. dopamine, kynurenine) and potentially-excitotoxic (glutamate)
neurotransmitters, and (v) a relative dearth of certain antioxidant
defenses [2]. Iron homeostasis in peripheral and neural tissues is tightly
regulated by a panoply of proteins controlling its absorption, extracel-
lular transport, cellular ﬂux, signaling activities, valence conﬁguration,
and intracellular storage [3–8]. The CNS maintains strict and fairly
autonomous control of its chemical microenvironment and the blood–
brain barrier (BBB) precludes free ﬂux of transferrin, ferritin, cerulo-
plasmin and other iron-regulating proteins from the systemic circula-
tion to the CNS. Cerebrovascular endothelial cells at the BBB bind
circulating diferric transferrin and the resulting complexes are
internalized. After dissolution of the complexes within endothelial
endosomes, apotransferrin is recycled to the blood and iron is exported
across the abluminal membrane, likely via ferroportin, to the interstitial
space [8,9]. Despite this meticulous control, iron progressively accumu-
lates in the mammalian CNS as a function of advancing age, and a
portion of the metal in the brain parenchyma and cerebrospinal ﬂuid
(CSF) remains redox-active. Within the normal human CNS, the iron is
preferentially sequestered in the basal ganglia, hippocampus, certain
cerebellar nuclei and other, largely subcortical, brain regions.Within the
diseased CNS, iron-derived ROS may facilitate pro-toxin bioactivation;
aberrant cell signaling, bioenergetic failure; proteosomal dysfunction,
protein aggregation and inclusion formation; electrophysiological de-
rangements; and synaptolysis, apoptosis and necrosis [10].
Pathological iron deposition and attendant oxidative stress (OS)
occur and may constitute an important therapeutic target in a host of
Table 1
Neurodegeneration with brain iron accumulation (NBIA).
Friedreich ataxia (FA)a
Pantothenate kinase-associated neurodegeneration (PKAN)
Phospholipase A2G6-associated neurodegeneration (PLAN)




a Not a classic NBIA syndrome (see text).
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focuses primarily on the clinical and neuroimaging aspects of a
group of heritable conditions known collectively as ‘neurodegenera-
tion with brain iron accumulation (NBIA)’ (Table 1). Interested
readers are referred elsewhere for detailed accounts of the molecular
pathology of these entities [8,11] and discussion of the acquired
conditions manifesting secondary CNS iron overload (Alzheimer
disease, Parkinson disease, amyotrophic lateral sclerosis, multiple
sclerosis, progressive supranuclear palsy, corticobasal degeneration,
superﬁcial siderosis, etc. [10,12–15]).
2. Iron neuroimaging
Magnetic resonance imaging (MRI) is sensitive to the presence and
concentration of non-heme iron in the living human brain and is
currently the modality of choice for the investigation and differential
diagnosis of NBIA syndromes. Iron deposits in brain and other tissues
cause local magnetic ﬁeld inhomogeneities with decreased T2 (trans-
verse) relaxation time and as a result appear hypointense (dark or low
signal) on T2-weighted and T2* images, particularly at higher ﬁeld
strengths [15–17]. Various pulse sequences have been employed to
visualize tissue iron, including spin echo, fast spin echo, and gradient
echo (GE) techniques (Fig. 1). Two commonly used and accepted
methods for estimating brain iron on MRI are the ﬁeld dependent
relaxivity increase (FDRI) method and calculations based on suscepti-
bility weighted imaging (SWI). The FDRI method is based on the
increase in the transverse relaxivity rate (R2=1/T2) with increasing
ﬁeld strength. Spin echo acquisitions are performed at two different
ﬁeld strengths (originally, 0.5 T and 1.5 T and more recently 1.5 T and
3.0 T). The repeated measurements obtained across two magnetic ﬁeld
strengths are then used for calculation of FDRIwhich has been shown to
correlate with tissue iron stores [18–20]. SWI is based on the
determination of local ﬁeld inhomogeneities resulting from the in-
ﬂuences of ferritin iron and other paramagnetic substances on the
product of signal amplitude and aﬁltered version of the signal phase at a
given ﬁeld strength and echo time [20]. SWI obviates the requirement
for scanning atmultiple ﬁeld strengths, an advantage over FDRI [21,22].
On the other hand, although heme iron (deoxygenated hemoglobin)
affects both R2 and phase and can confound precise ascertainment of
non-heme iron (ferritin, hemosiderin) levels, the impact on SWI is
substantially stronger. Indeed, the robust contrast between gray and
white matter on GE imaging of cerebral cortex may be due, at least in
part, to the greater blood volume of graymatter. SWI is alsomore prone
to distortion by air/bone/tissue interfaces and structural topography
relative to the magnetic ﬁeld [23].
Importantly, studies of healthy volunteers and subjects with PD
have revealed linear relationships between the relaxation rates, R2
and R2* (R2*=1/T2*) and regional brain iron concentrations
[19,20,24,25] estimated from earlier postmortem studies [26]
(Fig. 1). In a recent study of normal aging [20], high concentrations
of iron in the globus pallidus were detected at all ages and putaminal
iron proved to be reliable biomarker of advancing age by both FDRI
and SWI. Overall, FDRI appeared more sensitive than SWI for
measurement of tissue iron across multiple brain regions. On the
other hand, the high spatial resolution afforded by SWI may renderthis technique particularly appropriate for determination of subtle
intra-regional variations (e.g. hemosiderin deposits within small
infarcts) in given individuals followed longitudinally with serial scans
[20,27]. In a second report [28], the mean relaxation time (T2*) of the
putamen (along with thalamic volume and mean diffusivity) was
found to be the best predictor of physiological aging in healthy human
brain. Importantly, aging-related calciﬁcation of basal ganglia and
other neural structures may also generate T2/T2* hypointensities and
thereby confound iron measurements. However, MRI signals attrib-
uted to these minerals can be differentiated because calciﬁcations
similarly impact T1 (longitudinal) relaxation times whereas iron
deposits do not [29].
Further reﬁnements in MRI techniques to assess brain iron, e.g.
measurement of the relaxometry parameter, T2 rho and magnetic ﬁeld
correlation (MFC) imaging, are largely experimental [15] and beyond
the scope of this review.
Brain iron storesmay also be interrogated usingnon-MRImodalities,
such as transcranial sonography (TS) which yields hyperechoic signals
in regions of tissue metal sequestration. TS has been systematically
applied to detect excess midbrain iron in Parkinson disease and
dementia with Lewy bodies [30,31]. However, this approach suffers
from several shortcomings including relatively poor spatial resolution,
conﬁnement of imaging to certain brain regions, inadequate insonation
of temporal bone windows in a proportion of subjects, and the
possibility that factors other than iron, e.g. gliosis [32], may contribute
to the observed hyperechogenicity. The use of TS in NBIA is brieﬂy
alluded to in Section 3.5. Examples of pathological MR neuroimaging in
patients with NBIA are presented throughout the remainder of this
article, and the importance of this technology in the clinical investiga-
tion and differential diagnosis of the NBIA syndromes is emphasized.
3. Neurodegeneration with brain iron accumulation
NBIA encompasses a growing constellation of heritable disorders
resulting from diverse molecular pathologies. Friedreich ataxia (FA) is
not classically grouped with the NBIA. However, we elected to include
this important entity here because (i) the exclusion of FA from the
NBIA is rather arbitrary and based on historical precedent; as in the
case of the ‘classical’ NBIA, FA is a genetic, progressive neurodegen-
erative condition featuring prominent iron deposition in brain; (ii)
imaging of brain iron is a central theme of this review and several
recent reports of changing iron signals in FA cerebellum following
chelation therapy (see below) are pivotal to the current discussion;
and (iii) the reported clinical beneﬁts of iron chelators and
antioxidants in FA may inform the management of the notoriously
refractory ‘classical’ NBIA syndromes. Before considering the NBIAs
individually, there are some general concepts and characteristics
worthy of mention which apply to this group of disorders: (i) in some
instances, the implicated mutations directly impact the structure-
function of proteins known to participate in tissue iron homeostasis.
Prime examples of this are mutant frataxin in Friedreich ataxia (FA)
and L-ferritin in neuroferritinopathy. In other cases, as in pantothe-
nate-kinase 2-associated neurodegeneration (PKAN), the link be-
tween the protein abnormality and the development of NBIA remains
unknown or conjectural. (ii) With the exception of FA, the NBIAs are
rare conditions which many practicing pediatric and adult neurolo-
gists may encounter infrequently, if at all, outside of a tertiary referral
center. On the other hand, the increasing availability of MRI and
genetic testing is anticipated to bring more cases of established and
novel NBIA syndromes to medical attention. (iii) The vast majority of
NBIA cases feature extrapyramidal and/or cerebellar signs (involun-
tary movements and incoordination) at some point in their natural
history and corresponding abnormalities in the basal ganglia and
cerebellum on neuroimaging. This may be commensurate with the
fact that the basal ganglia, red nuclei and cerebellar dentate nuclei are
regions naturally predisposed to the accumulation of iron in the
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governing the remarkably heterogeneous distribution of iron in the
normal mammalian neuraxis are enigmatic. (iv). Although a number
of NBIA syndromes present in childhood or early adulthood (e.g. FA,
PKAN), others may remain asymptomatic until midlife or later (e.g.
aceruloplasminemia). The latter suggests that, akin to conditions such
as familial Alzheimer disease, normal CNS aging and/or environmen-
tal triggers may be required to ‘unmask’ the primary genetic defect.
(v) While some NBIA syndromes target the CNS almost exclusively
(e.g. PKAN), others exhibit substantial involvement of peripheral
tissues (e.g. aceruloplasminemia). Contrariwise, hereditary hemo-
chromatosis, a systemic disorder of body iron homeostasis, may
promote little or no excess iron deposition within the CNS [8] while
pathological iron stores in the liver and other organs may be sufﬁcient
to trigger airport metal detectors [33]! An appreciation of this clinical
variability is vital to the establishment of correct diagnoses and
further underscores the fact that the regulation of brain iron
metabolism is, in large measure, distinct from that in peripheral
tissues. (vi) Even within kindreds, clinical manifestations of NBIAmay
vary substantially in severity and tempo among affected individuals.
Sadly, these diseases tend to be relentlessly progressive and are
inevitably fatal. (vii) As a rule, the NBIAs are notoriously refractory to
deﬁnitive therapy, although certain interventions (e.g. baclofen for
spasticity; deep brain stimulation for tremor) may afford signiﬁcant
symptomatic relief in select patients. Treatment with clinically-
approved iron chelators (e.g. deferoxamine, which exhibits limited
blood–brain barrier penetrability) have rarely yielded signiﬁcant
beneﬁts and may be fraught with complications. There is even the
theoretical concern that mobilization of brain iron, even if pharma-
cologically achievable, might expose hitherto protected neural sub-
strates to the metal's toxic effects and thereby exacerbate the
condition. Still, recent advances in the delineation of the molecular
mechanisms responsible for the neurodegenerative processes, and the
advent of orally-bioavailable, brain-permeant metal chelators (e.g.
deferiprone) and antioxidants, offers hope that rational and effective
therapy for NBIA may be forthcoming.
3.1. Friedreich ataxia
Friedreich ataxia is an autosomal recessive neurodegenerative
condition and the most common of the heritable human ataxias. The
pathology is characterized by degenerationwithin the spinocerebellar
and pyramidal tracts, dorsal columns of the spinal cord, dorsal root
ganglia, and, to a lesser degree, the cerebellum and medulla [34].
Clinical manifestations generally become apparent before age 25 and
include progressive dysarthria, gait and limb ataxia (incoordination),
areﬂexia, loss of proprioception and vibration sense, pes cavus,
diabetes mellitus and hypertrophic cardiomyopathy. The latter may
give rise to secondary neurological morbidity (e.g. thromboembolic
cerebral infarction) and may be the cause of premature death in these
patients [32]. Iron accumulates in the brain (cerebellar dentate nuclei;
Fig. 2A) and myocardium and can be visualized by MRI and
histochemical stains (ferric ferricyanide/Prussian blue) [35–37]. Of
note, the restless leg syndrome (RLS) may be over-represented and
correlate with low circulating ferritin concentration in FA patients.
Evidence of altered brain iron homeostasis in both conditions may
suggest intersecting pathophysiologies at the cellular/molecular level
[38].
The defective gene in this disease is FRDA (encoded by a nuclear
gene) which codes for frataxin, a mitochondrial protein. Frataxin isFig. 1.Magnetic resonance imaging (MRI) of iron in human brain. A. Young (left) and elderly
(1.5 T; bottom). Increasing iron concentrations engender higher (brighter) FDRI signals but
FDRI, Field-Dependent Relaxation Rate (R2) Increase; SWI, susceptibility-weighted imaging.
(X-axis) estimated from published post-mortem data [26] and mean R2* values (Y-axis)
reconstruction based on T1-weighted images. CN, caudate nucleus (blue): Pu, putamen (renormally highly expressed in mitochondria-rich tissues such as brain,
heart, and skeletal muscle where it may assist in the assembly or
export of Fe–S clusters from mitochondria, heme biosynthesis and
mitochondrial iron storage [32,39]. Cells from FA patients exhibit a
marked reduction in frataxin levels usually accruing from an
expansion of a GAA trinucleotide repeat in intron 1 [35,40],
intramitochondrial iron trapping, and defective aerobic respiration
[39]. A detailed account of the pathomolecular effects of mutant
frataxin and its yeast homolog, Yfh1p has recently been published [8]
and will not be recapitulated here.
3.1.1. Treatment of Friedreich ataxia
Oral administration of the respiratory chain antioxidant, co-
enzyme Q and its congener, idebenone, has been shown to improve
certain cardiac indices in FA, but the impact of these agents on the
neurological aspects of the disease has thus far been negligible
[41,42]. A ray of optimism emerged in 2007 from a phase 1–2 study in
which the orally-active, membrane permeant iron chelator, defer-
iprone (3-hydroxy-1,2-dimethylpyridin-4-one) was administered to
nine adolescent FA patients with no overt cardiomyopathy [43].
Following a 6-month treatment period with 20 to 30 mg/kg/day, MRI
revealed a signiﬁcant reduction in the mean R2* signal in the
cerebellar dentate nuclei (Fig. 2B), an index of tissue iron stores
(see Section 2). Moreover, the investigators reported a clinically-
meaningful amelioration of peripheral neuropathy and ataxic gait in
the youngest patients, without evidence of signiﬁcant adverse
hematological or neurological effects. In a more recent study [44],
idebenone and deferiprone (each at 20 mg/kg/day) were adminis-
tered to 20 FA patients (ages 25–81) for 11 months. The therapeutic
responses were variable, but signiﬁcant improvement in kinetic
functions and in dentate nucleus iron deposition (determined by MRI
T2* values) was observed, respectively, in 13 and 14 subjects.
3.2. Pantothenate kinase-2-associated neurodegeneration
Pantothenate kinase-2-associated neurodegeneration (PKAN; a.k.a.
NBIA-1; formerly Hallervorden–Spatz syndrome) is an autosomal
recessive disorder characterized by mutations in the gene encoding a
mitochondrial pantothenate kinase (PANK2) at locus 20p13-p12.3 [45–
47]. The prevalence of PKAN is approximately 1–3 permillion [48].Most
PKAN patients present in childhood or young adulthood with
combinations of dystonia, parkinsonism, dysarthria, spasticity, seizures,
mental retardation, dementia, optic atrophy and pigmentary retinop-
athy [45,49,50]. An onset with clumsiness and gait disturbance around
age 3 years followed soon thereafter by asymmetric lower limbdystonia
is classic. Atypical cases feature a slowly-progressive neuropsychiatric
syndrome in addition to the movement disorder [45]. Psychiatric
manifestations include obsessive–compulsive disorder, schizophrenia-
like psychosis and depression. Cognitive dysfunction is variable, is
generally more severe in patients with earlier–onset disease, may
precede motor impairment, and often implicates attention and
executive functions [51]. Rare cases of PKAN may present in adulthood
and mimic PD or amyotrophic lateral sclerosis [50,52–54]. Another
unusual phenotype is HARP (hypoprebetalipoproteinemia, acanthocy-
tosis, retinitis pigmentosa, and pallidal degeneration). Initially con-
strued as a distinct NBIA syndrome, the original HARP patient was
subsequently discovered to harbor a PANK2 mutation placing this
condition squarely within the PKAN disease spectrum [55].
The majority of the affected (both classical and atypical) andmany
pre-symptomatic individuals with PKAN exhibit the “eye-of-the-tiger(right) group means for FDRI images (acquired at 1.5 T and 3.0 T; top) and SWI images
lower (darker) SWI phase signals. “64” denotes use of 64-pixel kernel Hanning ﬁlter.
Adapted from [20], with permission. B. Correlation of age-adjusted iron concentrations
in human basal ganglia. The subcortical regions examined are depicted in the 3D
d); GP, globus pallidus (green). Adapted from [16], with permission.
Fig. 2.MRI of brain iron stores in Friedreich ataxia (FA). A. Mean R2* values reﬂecting tissue iron concentrations are signiﬁcantly greater in the cerebellar dentate nucleus (i), but not
in globus pallidus (ii), of FA patients (squares) relative to controls (circles) and increase with age in both regions (although the rate of increase for the dentate nucleus appears to be
lower in the FA subjects). Adapted from [37], with permission. B. Absolute and relative changes in R2* of dentate nucleus in nine FA patients after 6-month oral therapy with the iron
chelator, deferiprone (DFP). Mean R2* measurements are signiﬁcantly lower after treatment (bottom of bars) relative to pre-treatment values (top of bars).
Adapted from [43], with permission.
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surrounded by a ring of hypointensity in the globus pallidus attributed
to tissue vacuolization/gliosis and pathological iron deposits, respec-
tively (Fig. 3) [56]. Brown discoloration of the basal ganglia due toFig. 3. Brain MRI of subject with pantothenate kinase-2 associated neurodegeneration
(PKAN). T2*-weighted echo-planar sequence demonstrates characteristic “eye-of-the-
tiger” sign in the globus pallidus (arrow).
Modiﬁed from [105], with permission.excessive iron sequestration is noted at autopsy. Histochemical
staining with Perls' method reveals granular iron deposits scattered
throughout the neuropil and within microglial cells and astrocytes of
the globus pallidus and substantia nigra pars reticulata. Similar
concretions and spheroid bodies (focal axonal swellings) occur in the
subthalamic nucleus of Luys and within cerebral gray and white
matter. Although ‘Hallervorden–Spatz’ cases exhibiting various
pathological changes in peripheral blood lymphocytes have been
reported [57,58], these have not been documented in genetically-
conﬁrmed PKAN.
PANK2 catalyzes the phosphorylation of pantothenate (vitamin
B5) in the coenzyme A biosynthetic pathway. Phosphopantothenate,
the product of the PANK2 reaction normally condenses with cysteine
in the next step of the pathway. Cysteine has been reported to
accumulate in the globus pallidus of persons diagnosed with
Hallervorden–Spatz syndrome [59]. Hayﬂick and colleagues initially
posited that the excessive tissue cysteine, an amino acid with iron-
chelating properties, may mediate the regional accumulation of iron
in these patients. Moreover, in the presence of transition metals,
cysteine undergoes rapid autoxidation yielding reactive oxygen and
sulfur species [31,60] which may promote oxidative neuronal injury
in the basal ganglia of PKAN subjects and associated extrapyramidal
symptoms [47,49]. The recent identiﬁcation of an NBIA syndrome
(phospholipase A2G6-associated neurodegeneration (PLAN) — see
below) with clinical phenotypes overlapping those of PKAN, but
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a stiff challenge to the ‘cysteine hypothesis’ of iron deposition in these
disorders.
Unfortunately, there is at present no speciﬁc treatment with
proven efﬁcacy for persons afﬂicted with PKAN. Iron chelation
therapy with deferoxamine and administration of vitamin B5 have
been attempted without evidence of beneﬁt [61]. Oral or intrathecal
baclofen and stereotactic pallidotomymay provide symptomatic relief
but have no known disease-modifying effects [62,63].
3.3. Phospholipase A2G6-associated neurodegeneration
As alluded to in the previous section, genetic lesions distinct from
mutations in PANK2 may present a neurological picture virtually
identical to that of PKAN. As a case in point, mutations in the gene
encoding a calcium-independent group VI phospholipase A2 (PLA2G6)
have been implicated in some children with NBIA initially diagnosed
as having PKAN [45,64]. Several distinct autosomal recessive
syndromes have been reported in patients with phospholipase
A2G6-associated neurodegeneration (PLAN; also referred to as
NBIA-2). Some present with early psychomotor retardation, cerebellar
signs, spasticity and visual disturbances; others display dystonia–
parkinsonism and dementia associated with frontotemporal atrophy
[65]. Importantly, T2 signal attenuation indicating iron accumulation
in the substantia nigra and striatum are seen in many, but not all, of
the affected individuals [66]. Moreover, in contradistinction to PKAN,
the “eye-of-the-tiger sign” is not characteristic of PLAN (Fig. 4).
The PLA2G6 enzyme has been implicated in arachidonic acid
release, prostaglandin and leukotriene synthesis, phospholipid remo-
deling, and apoptosis [67] and has previously been associated with
forms of infantile neuroaxonal dystrophy [68] and Karak syndrome
[69]. It is unclear whether pathological brain iron trapping in patients
with phospholipase A2G6-associated neurodegeneration (PLAN)
accrues from alterations in lipid neurochemistry or from some other
unknown action of the mutant enzyme.Fig. 4. T2-weighted MRI of a 9-year-old patient with phospholipase A2G6-associated
neurodegeneration (PLAN). There is symmetrical signal attenuation in the globus
pallidus compatible with excessive iron deposition (arrow).
From [66], with permission.3.4. Fatty acid hydroxylase-associated neurodegeneration
Autosomal recessive NBIA may result from mutations in the fatty
acid hydroxylase gene, FA2H [70]. Mutant FA2H had previously been
linked to types of leukodystrophy and hereditary spastic paraplegia
[71]. Subjects with FA2H-associated neurodegeneration (FAHN) and
NBIA present with childhood–onset gait disorder, marked ataxia,
dystonia and spastic paraparesis, but no optic atrophy, pigmentary
retinopathy or cognitive decline. On MRI, FAHN patients exhibit
bilateral T2 hypointensities of the globus pallidus compatible with
excess iron, severe pontocerebellar atrophy, mild diffuse cortical
atrophy, thinning of the corpus callosum and conﬂuent periventri-
cular white matter T2 hyperintensities [70–72] (Fig. 5). The white
matter abnormalities in FAHN may represent syndromic overlap with
the aforementioned FA2H-related leukodystrophy. FA2H catalyzes the
formation of 2-hydroxylated fatty acids that are necessary for the
biosynthesis of ceramide, galactosylceramide and sulfatide constitu-
ents of normal CNS myelin [73].
3.5. Kufor-Rakeb disease
Kufor-Rakeb Disease (KRD) is an autosomal recessive NBIA
disorder ﬁrst described in 1994 [74] resulting from mutations in the
ATP13A2 gene on chromosome1p36 [75]. The gene codes for a putative
lysosomal P-type transmembrane cation-transporting ATPase of
uncertain function [76,77]. Symptoms generally begin in the 2nd or
3rd decade and may be heralded by neuropsychiatric abnormalities
such as mania, delusions and insomnia. Characteristic clinical features
include parkinsonism (which may be transiently L-dopa-responsive),
pyramidal dysfunction (spastic weakness) and supranuclear gaze
palsies. Cognitive deterioration and dementiamay ormay not develop.
Elevated CSF kynurenine levels have been reported but are not speciﬁc
to this condition. The disease is usually slowly progressive, although a
subacute course rendering victims bed-bound within the ﬁrst few
years may occur [74,77]. Brain MRI in KRD reveals generalized cortical
and subcortical atrophy and hypointensities of the caudate and
putamen on T2* sequences (Fig. 6) compatible with augmented iron
deposition (but which awaits neuropathological conﬁrmation). In a
recently-reported Chilean family [78], a 45 year-old mother with
compound heterozygosity for mutant ATP13A2 exhibited parkinson-
ism (Hoehn and Yahr stage 2), dementia, symmetrically reduced
putaminal tracer uptake on dopamine transporter (DAT) imaging,
global brain atrophy, and T2/T2* hypointensities in caudate and
putamen consistent with abundant iron. Children heterozygous for
mutant ATP13A2 all manifested subtle signs of parkinsonism (reduced
arm swing, limb rigidity, mild postural tremor), but T2/T2* imaging, TS
and DAT single photon emission computed tomography scans of the
basal ganglia were within normal limits.
3.6. Aceruloplasminemia
Ceruloplasmin is an abundant plasma α2-glycoprotein that is
synthesized primarily, but not exclusively, in the liver. In the presence
of ceruloplasmin, ferrous ion (Fe2+) becomes oxidized to ferric ion
(Fe3+) with concomitant complete reduction of molecular oxygen. To
date, the only clearly deﬁned physiological function of ceruloplasmin
is its ferroxidase activity [79,80]. The holoprotein contains six copper
atoms, three of which form a trinuclear cluster that activates oxygen
required for catalytic activity. The ferroxidase activity of ceruloplas-
min facilitates iron efﬂux from cells. Ceruloplasmin oxidizes ferrous
ions following their transfer to the cell surface via ferroportin andmay
foster shedding and delivery of ferric iron to transferrin in the
extracellular milieu. A glycosylphosphatidylinositol (GPI)-anchored
ceruloplasmin bound to astroglial cell membraneswas found to be the
major isoform of this protein in the CNS. Moreover, the ability of
astrocytes isolated from ceruloplasmin-deﬁcient mice to purge
Fig. 5. Fatty acid 2-hydroxylase associated neurodegeneration (FAHN). MR images of the brain from four published cases are depicted [70–72]. There is marked pontocerebellar
atrophy (yellow arrows), mild cerebral atrophy, and thinning of the corpus callosum (magenta arrows) in all cases. T2-weighted images indicate hypointensities of the globus
pallidus (arrowheads) consistent with iron deposition, and subcortical/periventricular white matter hyperintensities (blue arrows).
Adapted from [70], with permission.
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ceruloplasmin as an important component of the iron-regulatory
machinery in the mammalian CNS [81].
In 1987, Miyajima and colleagues [82] described a 52-year-old
Japanese woman who presented with extrapyramidal symptoms
associated with signal hypointensities of the basal ganglia and
cerebellum on MRI compatible with excessive iron sequestration.
There was also retinal degeneration, diabetes mellitus, mild anemia,
low plasma iron concentrations, elevated plasma ferritin levels, severe
hepatic iron overload and undetectable serum ceruloplasmin. A loss-
of-function mutation in the ceruloplasmin gene (chromosome 3q25)
was discovered on nucleotide sequence analysis [83]. Additional cases
bearing distinct point mutations and splice-variants in the cerulo-
plasmin gene have since come to light, with most causing defective
assembly of the trinuclear copper cluster [84–86]. Neuroimaging
features have been consistent with pathological iron deposition in
basal ganglia, thalamus and cerebellum (Fig. 7). Patients homozygous
for this defect manifest serious parenchymal iron overload affecting
the liver, pancreas and CNS. CNS involvement is often diagnosed at
midlife, is progressive, and targets the basal ganglia (choreathetosis,
dystonia, dysarthria, dementia), the cerebellum (ataxia) and retina
(pigmentary degeneration with visual loss). Circulating ceruloplas-
min levels and attendant ferroxidase activity in the homozygouscondition are nil or negligible. Subjects heterozygous for mutant
ceruloplasmin exhibit ~50% reduction in circulating protein levels
(“hypoceruloplasminemia”) and display subtle signs of cerebellar
dysfunction on careful testing [87].
3.6.1. Treatment of aceruloplasminemia
A few clinical reports suggest that treatmentwith the Fe3+ chelator,
deferoxaminemay have some role in preventing iron accumulation and
related symptoms in individuals with aceruloplasminemia [88].
However, most initial attempts to purge brain and body iron with
deferoxamine in these patients have proved unsuccessful, possibly
because the iron burden in these individuals favors the Fe2+ state in the
absence of normal ferroxidase activity [89]. To circumvent this
conundrum, Yonekawa and colleagues [89] ﬁrst administered fresh
frozen plasma (450 mL i.v./week) for 6 weeks to replenish blood
ceruloplasmin levels and restore ferroxidase activity. Thereafter,
deferoxamine (1 g i.v./day) was administered for an additional
6 weeks to deplete ferric iron stores. Although MR images of the brain
in this test case remained unchanged following treatment, there was
unprecedented improvement in choreoathetosis and ataxia and
resolution of abnormal high-voltage sharp activity on electroencepha-
lography. Neurological improvements have also been reported after
administration of oral zinc sulfate and the iron chelator, deferasirox [90].
Fig. 6. Kufor-Rakeb disease (KRD). T2*-weighted MRI demonstrating bilateral caudate
and putaminal hypointensities (arrow) suggestive of augmented iron deposition.
From [77], with permission.
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The primary (possibly sole) function of ferritin is the sequestration
and storage of metabolically-inert iron. Mammalian ferritin can
accommodate up to 4500 iron atoms in its internal cavity. The
apoprotein shell is comprised of 24 subunits of two types, a 19 kDa
light subunit (L-subunit) and a 21 kDa heavy subunit (H-subunit)Fig. 7. Aceruloplasminemia. Gradient echo (GE) T2*-weighted images reveal profound hypoi
and midbrain with ventriculomegaly in a 56 year-old male proband (A–C). Similar, but less ﬂ
proband's sister (D–F).
From [88], with permission.[3,91]. Fe2+ incorporated into the ferritin shell is oxidized to Fe3+ by
the ferroxidase activity of the H-subunit, while the L-subunit largely
mediates iron-core nucleation. In 2001, Curtis et al. [92] reported a
novel, dominantly-inherited neurodegenerative disorder character-
ized by extrapyramidal signs and excessive iron deposition in the
basal ganglia. Initially, all those affected originated from Northern
England (Cumbrian region) and presented at ages 40–55 with
choreoathetosis, rigidity, dystonia and spasticity, but no cerebellar
involvement or cognitive decline [93,94]. MRI of the brain in patients
with this condition, termed neuroferritinopathy (or NBIA-3), reveals
extensive mixed-signal abnormalities in the basal ganglia, thalami
and red nuclei (Fig. 8) which may correlate with disease progression
[92,94,95].
In the Cumbrian cohort, the genetic defect was mapped by linkage
analysis to locus19q13.3 containing thegene for ferritin L-chain [92]. The
samemutation appears to have arisen independently in France [96] and
at least three additional families with neuroferritinopathy have been
recognized [97]. In the French family, notable neurological signs included
dystonic dysarthrophonia, blepharospasm, and cerebellar dysfunction.
Variations in the molecular pathology of the mutant L-ferritin genes in
these families were recently reviewed [8]. It has been postulated that
disruption of the C-terminus of L-ferritin compromises protein stability
and function and that “unshielded” cytosolic iron resulting from the
assembly of incompetent holoferritin might facilitate oxidative tissue
damage in patients with neuroferritinopathy [98].
Neuropathological examination of the brains in these cases
revealed cystic necrosis of the globus pallidus with variable
involvement of surrounding structures. There was prominent accu-
mulation of stainable iron and ferritin, often in the form of discrete
inclusions, in neurons of the globus pallidus and within microglia and
oligodendrocytes of the forebrain and cerebellum. Importantly, the
Cumbrian patients showed no evidence of systemic iron overload or
diabetes, and their serum ferritin levels were surprisingly low
(hypoferritinemia). Although liver function tests in these subjects
were normal [92], unique hepatocytic concretions have beenntensities (iron deposition) in the caudate nucleus, putamen, globus pallidus, thalamus
orid, lesions of the basal ganglia and thalamus are demonstrable on neuroimaging of the
Fig. 8. A case of neuroferritinopathy. T2-weighted MRI of the brain shows mixed hyper-
and hypointensities affecting the putamen, globus pallidus and thalamus symmetri-
cally.
From [95], with permission.
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cited in [8]). In one kindred, there were abundant intranuclear and
intracytoplasmic bodies containing ferritin and iron in oligodendrog-
lia, astrocytes, renal tubular epithelium, dermal ﬁbroblasts and
muscle capillary endothelial cells [99] prompting one investigator to
consider muscle biopsy as a potential diagnostic test for neuroferri-
tinopathy [100]. Attempts at iron chelation in this disease have not
yielded any clinical beneﬁts to date [93].
3.8. Differential diagnosis
In subjects with aceruloplasminemia, the systemic abnormalities of
iron metabolism may be appreciated prior to the onset of neurological
symptoms. Such persons may be misdiagnosed as having type 1
hereditary hemochromatosis and subjected to inappropriate serial
phlebotomies thatmightworsen the anemia. These two diseases can be
distinguished by determination of plasma transferrin saturation, which
is elevated in hemochromatosis but low in aceruloplasminemia [80].
PatientswithWilsondiseasemay also exhibit symptomsreferable to the
basal ganglia and subnormal circulating ceruloplasmin levels. However,
in contradistinction to Wilson disease, individuals with aceruloplasmi-
nemia do not display increased hepatic and urinary copper levels or
corneal copper deposition (Kaiser–Fleischer rings) on slit-lamp exam-
ination [80]. Cerebellar atrophy/dysfunction and T2 signal loss (iron
deposition) in the dentate nuclei may predominate in Friedreich ataxia
and hypoceruloplasminemia. These conditions exhibit a similarmode of
inheritance (autosomal recessive) but can be readily distinguished by
dorsal column and cardiac involvement in the former, and diminished
circulating ceruloplasmin in the latter. Low ceruloplasmin levels also
complicate acquired copper deﬁciency [101], but the associated
myelopathy is not characteristic of heritable hypoceruloplasminemia.
Differentiation of FA fromacquired vitamin E deﬁciency (asmight occur
with micronutrient malabsorption) or autosomal recessive ataxia with
vitamin E deﬁciency (AVED)may prove challenging on clinical grounds[2,101] and requiremeasurement of blood vitamin E levels or testing for
mutant FRDA orα-tocopherol transfer protein. PKAN, PLAN, FAHN, KRD
and neuroferritinopathy all manifest prominent extrapyramidal dys-
function and iron deposition in basal ganglia. The absence of peripheral
iron overload in these conditions, and possible hypoferritinemia in
neuroferritinopathy, differentiate these forms of NBIA from acerulo-
plasminemia [80,92]. Although T2* hypointensities (and other iron-
sensitive MRI sequences) of the caudate and/or lenticular nuclei are
characteristic of most NBIA disorders, the “eye-of-the-tiger” sign most
often denotes PKAN and should prompt molecular testing for PANK2
mutations. Rarely, this MRI sign may occur in NBIA cases harboring
normal PANK2 genes and has been reported in non-NBIA conditions
including Leigh's disease, organic acidurias and acquired dystonias
[56,102,103]. In the presence of homogeneous T2 signal attenuation in
basal ganglia, but no “eye-of-the-tiger” sign, genetic testing for PLAN or
other NBIA may be warranted [45]. Mixed hyper- and hypointense
signals in the basal ganglia and thalamus on T2 MRI may favor a
diagnosis of neuroferritinopathy, especially in the context of autosomal-
dominant inheritance. Not all patients with PLAN show brain iron
overload and the absence of basal ganglia hypointensities on MRI does
not exclude this diagnosis in cases presenting with infantile neuroax-
onal dystrophy [45,65].
4. Conclusions
Heritable perturbations in brain and body iron homeostasis and
pathological deposition of this redox-active metal in the CNS have been
recognized in a number of pediatric and adult neurodegenerative
conditions. In this article, we examined the clinical, pathological and
neuroimaging features of FA, PKAN, PLAN, FAHN, KRD, aceruloplasmi-
nemia, and neuroferritinopathy. Iron trapping in erythroblast mito-
chondria and cerebellar hypoplasia occur in X-linked sideroblastic
anemia with ataxia [104]. The latter was not reviewed here because, to
the author's knowledge, no empirical evidence of brain iron accumu-
lation has thus far been reported in this condition. Similarly, although
heterozygosity for common gene (HFE) mutations responsible for
hereditary hemochromatosis have been promulgated as risk factors for
‘acquired’ human neurological disorders (Alzheimer disease, Parkinson
disease, amyotrophic lateral sclerosis, stroke), epidemiological data on
this topic are highly conﬂicting and conjecture regarding the potential
impact of the defective alleles on brain iron homeostasis remains
unsubstantiated [8]. That being said, it is almost axiomatic that
additional, genetically-based NBIA conditions will come to medical
attention given the rapid pace of discovery of novel proteins governing
diverse aspects of iron metabolism, advances in molecular genetic
testing, and the continual reﬁnements (both hardware and software) in
MRI and other neuroimaging techniques responsive to tissue iron.
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